Physician

Gustavo A Fonseca, MD

According to 2025 Medicare claims, Gustavo Fonseca, MD (NPI: 1063478766) practices hematology/oncology in the Homosassa Springs, FL market, with the plurality of this provider's patient population coming from Citrus, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34461-9187.

Fonseca's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 989 traditional Medicare patients, billed 277,582 HCPCS/CPT codes, and received $4,352,102 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,261 prescription claims across 266 beneficiaries totaling $6,781,622 in drug costs, led by Revlimid (Lenalidomide). DME data shows 65 claims. Open Payments data shows 204 records totaling $1,066,325. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,669,962 to $6,781,622. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,735 to $2,083.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,028	347,945	$3,355,935
2016	1,095	325,283	$3,387,940
2017	1,203	360,677	$3,506,918
2018	1,309	409,169	$4,605,012
2019	1,324	400,321	$4,827,879
2020	1,158	339,654	$4,375,856
2021	1,064	264,981	$4,648,390
2022	1,042	307,756	$5,112,926
2023	953	324,946	$4,229,147
2024	989	277,582	$4,352,102

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	192	880	$1,669,962
2016	202	1,117	$2,487,515
2017	197	1,155	$2,294,427
2018	213	1,123	$2,215,441
2019	213	1,091	$2,349,334
2020	219	1,206	$3,834,060
2021	210	951	$3,047,594
2022	250	1,030	$4,547,886
2023	228	1,040	$4,391,223
2024	266	1,261	$6,781,622

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	26	147	$84,130
2016	N/R	109	$67,794
2017	23	155	$57,618
2018	24	160	$44,857
2019	N/R	81	$38,047
2020	N/R	127	$41,340
2021	N/R	128	$43,312
2022	N/R	121	$2,949
2023	11	95	$13,178
2024	N/R	65	$1,487

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	442	1,708	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	370	670	$64
96372	Injection of drug or substance under skin or into muscle	266	872	$10
36415	Insertion of needle into vein for collection of blood sample	855	2,661	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	852	2,678	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	97	2,716	$1,728,045
Ibrance	Palbociclib	52	1,456	$823,180
Venclexta	Venetoclax	35	1,035	$556,797
Brukinsa	Zanubrutinib	31	930	$437,904
Zejula	Niraparib Tosylate	23	690	$395,595

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	34	$1,111
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	31	$376

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	150	$21,392	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	54	$1,044,932	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Gustavo A. Fonseca, MD?

Tedicare shows public-source Medicare data for Gustavo A. Fonseca, MD (NPI 1063478766), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gustavo A. Fonseca, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Gustavo A. Fonseca, MD?

Gustavo A. Fonseca, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Gustavo A. Fonseca, MD have Open Payments data?

Gustavo A. Fonseca, MD has 204 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.